Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease

Neurology

Volumn 47, Issue 3, 1996, Pages 718-726

  Wilson, J M ^a   Levey, A I ^b   Rajput, A ^c   Ang, L ^d   Guttman, M ^a   Shannak, K ^e   Niznik, H B ^f   Hornykiewicz, O ^a   Pifl, C ^a   Kish, S J ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF VIENNA   (Austria)

^f ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3 O METHYLDOPAMINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 5 HYDROXYINDOLEACETIC ACID; DIHYDROTETRABENAZINE; DIHYDROXYPHENYLACETIC ACID; DOPA; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; SEROTONIN; TRITIUM;

AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; IDIOPATHIC DISEASE; LIGAND BINDING; MALE; NEUROCHEMISTRY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 9544238113     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.718     Document Type: Article

References (43)

1. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 1960;38:1236-1239.
2. Zhong X-H, Haycock JW, Shannak K, et al. Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov Disord 1995;10:10-17.
3. Gjedde A, Léger GC, Gumming P, et al. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis. J Neurochem 1993; 61:1538-1541.
4. Schoemaker H, Pimoule C, Arbilla S, et al. Sodium-dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 1985;329:227-235.
5. Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1988;26:551-557.
6. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
7. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-2260.
8. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1986;45:1-18.
9. Pakkenberg B, Moller A, Gundersen HJG, Dam AM, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30-33.
10. Janowsky A, Vocci F, Berger P, et al. [3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 1987;49:617-621.
11. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer's type. Brain Res 1994;637:262-266.
12. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43-49.
13. Mizukawa K, McGeer EG, McGeer PL. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson's disease, Alzheimer's disease, and neurologically normal controls. Mol Chem Neuropathol 1993;18:133-144.
14. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer's type. Brain Res 1994;637:262-266.
15. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate. J Neurochem 1991;56:192-198.
16. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34.
17. Laihinen AO, Rinne JO, Nâgren KA, et al. PET studies on brain monoamine transporters with carbon-11CIT in Parkinson's disease. J Nucl Med 1995;36:1263-1267.
18. Innis RB. Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease. Eur J Nucl Med 1994;21:l-5.
19. Kish SJ, Shannak K, Hornykiewicz 0. Uneven pattern of do-pamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:867-880.
20. Wilson JM, Nobrega JN, Carroll ME, et al. Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J Neurosci 1994; 14:2966-2979.
21. Madras BK, Spealman RD, Fahey MA, et al. Cocaine receptors labeled by [3H]2-carbomethoxy-3-(4-fluorophenyl)tropane. Mol Pharmacol 1989;36:518-524.
22. Scherman D, Raisman R, Ploska A, Agid Y. 3H-Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131-1136.
23. Miller GW, Heilman CJ, Perez JT, et al. Altered striatal dopamine transporter immunoreactivity in Parkinson's disease. Soc Neurosci Abstr 1995;21:1251.
24. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-1723.
25. Shimada S, Kitayama S, Lin C-L, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991;254:576-587.
26. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254: 528-529.
27. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976; 38:271-276.
28. Kish SJ, Shannak KS, Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann Neurol 1987;22:386-389.
29. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-464.
30. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35: 494-498.
31. Niznik HB, Tyndale RF, Sallee FR, et al. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR 12,935 binding proteins. Arch Biochem Biophys 1990;276: 424-432.
32. Soucy JP, Mrini A, Lafaille F, Doucet G, Descarries L. Assessment of WIN 35428 and GBR 12935 as quantitative markers of dopamine (DA) innervation density in brain. J Nucl Med 1995;36:118P-119P.
33. Pristupa ZB, Wilson JM, Huffman BJ, Kish SJ, Niznik HB. Pharmacological heterogeneity of the cloned and native human dopamine transporter: dissociation of [3H]WIN 35428 and [3H]GBR 12,935 binding. Mol Pharmacol 1994;45:125-135.
34. Eshleman AJ, Neve RL, Janowsky A, Neve KA. Characterization of a recombinant human dopamine transporter in multiple cell lines. J Pharmacol Exp Ther 1995;274:276-283.
35. Milner HE, Beliveau R, Jarvis SM. The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim Biophys Acta 1994;1190:185-187.
36. Berger SP, Farrell K, Conant D, Kempner ES, Paul SM. Radiation inactivation studies of the dopamine reuptake transporter protein. Mol Pharmacol 1994;46:726-731.
37. Kaufman MJ, Spealman RD, Madras BK. Distribution of cocaine recognition sites in monkey brain. I. In vitro autoradiography with [3H]CFT. Synapse 1991;9:177-187.
38. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci Lett 1994;173:l-4.
39. Vander Borght TM, Kilbourn MR, Desmond TJ, Kühl DE, Frey KA. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
40. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996;23:467-471.
41. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16: 3507-3510.
42. Giros B, Wang Y-M, Suter S, et al. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994;269:15985-15988.
43. Vaughan RA. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping. Mol Pharmacol 1995;47:956-964.